𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immune cells as anti-cancer therapeutic targets and tools

✍ Scribed by Magnus Johansson; Tingting Tan; Karin E. de Visser; Lisa M. Coussens

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
126 KB
Volume
101
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Chronic inflammation is a contributing factor to overall cancer risk as well as cancer promotion and progression; however, pathways regulating onset of cancer‐promoting inflammatory responses are still poorly understood. Clinical data suggest that deficient anti‐tumor cell‐mediated immunity, in combination with enhanced pro‐tumor humoral and/or innate immunity (inflammation), are significant factors influencing malignant outcome. Here, we discuss therapeutic implications from clinical data and experimental studies using de novo immune‐competent mouse models of cancer development that together are revealing molecular and cellular mechanisms underlying interactions between immune cells and evolving neoplastic cells that regulate cancer outcome. Understanding the functionally significant links between adaptive and innate immunity that regulate cancer development will open new therapeutic opportunities to manipulate aspects of immunobiology and minimize lethal effects of cancer development. J. Cell. Biochem. 101: 918–926, 2007. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Glial cells as targets for cytotoxic imm
Glial cells as targets for cytotoxic immune mediators
✍ Tracey Benn; Christopher Halfpenny; Neil Scolding 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract Oligodendrocytes and Schwann cells are the glia principally responsible for the synthesis and maintenance of myelin. Damage may occur to these cells in a number of conditions, but perhaps the most studied are the idiopathic inflammatory demyelinating diseases, multiple sclerosis in the

Wnt/β-catenin-pathway as a molecular tar
Wnt/β-catenin-pathway as a molecular target for future anti-cancer therapeutics
✍ Susanne Dihlmann; Magnus von Knebel Doeberitz 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 213 KB

Conventional chemotherapeutic drugs used for the treatment of cancer patients in advanced stages have yielded only limited benefit, regarding survival time not to mention cure of the patients. To improve the clinical outcome of cancer, agents aimed at novel molecular targets are required. Colorectal

Folate receptor-targeted immunotherapy:
Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells
✍ Yingjuan Lu; Emanuela Sega; Philip S. Low 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 202 KB 👁 1 views

We previously exploited the frequent overexpression of folate receptors on cancer cells to decorate malignant cell surfaces selectively with folate-hapten conjugates. In antihapten-immunized hosts, this targeted localization of foreign haptens to tumor cells led to rapid accumulation of autologous a

The Shiga toxin B-subunit targets antige
The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity
✍ Benoit Vingert; Olivier Adotevi; Delphine Patin; Steffen Jung; Protul Shrikant; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 438 KB 👁 1 views

## Abstract The non‐toxic B‐subunit of Shiga toxin (STxB) interacts with the glycolipid Gb~3~, which is preferentially expressed on dendritic cells (DC) and B cells. After administration of STxB chemically coupled to OVA (STxB‐OVA) in mice, we showed that the immunodominant OVA~257–264~ peptide res

ErbB4 increases the proliferation potent
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy
✍ Alex Starr; Joel Greif; Akiva Vexler; Maia Ashkenazy-Voghera; Valery Gladesh; Ch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 218 KB 👁 1 views

## Abstract Clinical and experimental data suggest that ErbB‐4, a member of the epidermal growth factor receptor family, may have a role in cancer progression and response to treatment. We found recently, using a retrospective clinical analysis, that expression of ErbB‐4 receptor is correlated with